Cervical Cancer Diagnostic Test Market Size, Outlook, Trends Report 2032

Cervical Cancer Diagnostic Test Market Insights

According to Zion Market Research, the global Cervical Cancer Diagnostic Test Market was worth USD 8.25 Billion in 2023. The market is forecast to reach USD 13.05 Billion by 2032, growing at a compound annual growth rate (CAGR) of 5.22% during the forecast period 2024-2032.

The report offers a comprehensive analysis of the market, highlighting the factors that will determine growth, potential challenges, and opportunities that could emerge in the Cervical Cancer Diagnostic Test Market industry over the next decade.

Request Free Sample

Amongst the types of cancer identified as of now, cervical cancer is the one most prevalent amongst women. Research also states that 90% of the cases of cervical cancer could be attributed to HPV infection. The diagnosis happens through smear screening. The last few years have seen a substantial increase in the population of female smokers. Plus, the frequency of unsafe sex is increasing among teenagers. Therefore, the rate of cervical cancer is increasing in the young population.

Covid Impact Analysis

The outbreak of COVID-19 has escalated the cervical cancer diagnostic tests, more so as the WHO has certified that those suffering from chronic diseases like cancer, and diabetes are more likely to contract Corona. These patients are trying to be doubly sure about the complexities so that utmost care can be taken amidst the ongoing pandemic. The market for cervical cancer diagnostic tests is not expected to stand still by any means, looking at the situation on the whole.

Cervical Cancer Diagnostic Test Market: Dynamics

The global cervical cancer diagnostic test market is significantly driven by the rise in the percentage of HPV in the female population. Lack of hygiene and non-awareness of cervical cancer in women is one of the significant factors to boost the need for cervical cancer diagnostic tests in women.

According to the CDC, more than seven million people acquire HPV in the U.S. Besides, changes in lifestyle, and availability of medical support are expected to propel the market growth. Genetic causes in women are also anticipated to contribute to the market growth in the coming years.

Cervical Cancer Diagnostic Test Market: Report Scope

Cervical Cancer Diagnostic Test Market: Segmentation Analysis

Segmentation Analysis by Test 

Based on the test, the global market of cervical cancer diagnostic test market is segmented as Pap smear tests, colposcopy, HPV testing, endocervical curettage (ECC), and others.

The Pap smear tests accounted for a significant share registering a high CAGR in the past few years. In addition, it is expected to continue dominating in the coming years. Factors such as growing awareness and low test prices are likely to influence commercial growth. The HPV testing segment is anticipated to have a second leading share attributed to the rise in incidences of HPV infections in the population.

Segmentation Analysis by End-User

Based on end-users, the global market of cervical cancer diagnostics test market is trifurcated into hospitals, laboratories, and others. The hospitals segment was the leading segment in 2023. The segment is expected to continue its dominance during the forecast period.

Cervical Cancer Diagnostic Test Market: Regional Analysis

North America held a significant share owing rise in awareness and presence of key players. Moreover, developed medical infrastructure offers lucrative opportunities for market development shortly. The Asia Pacific is the second leading market for cervical cancer diagnostic tests owing to the large population with unmet medical needs. The rise in the geriatric population is one of the major reasons for growth within regional markets.

Request Free Sample

Cervical Cancer Diagnostic Test Market: Competitive Analysis

Some of the key players in the cervical cancer diagnostic test market include;

• Abbott Laboratories
• Becton
• Dickinson and Company
• Femasys Inc.
• Hologic Inc.
• Oncohealth Corp
• Quest Diagnostics Inc
• QIAGEN and Zilico Ltd.

The Global Cervical Cancer Diagnostic Test Market is segmented into:

By Test:

• Pap Smear Tests
• Colposcopy
• HPV Testing
• Endocervical Curettage (ECC)
• Others

By End-User:

• Hospitals
• Laboratories
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa